Definium Therapeutics, Inc. (DFTX) News
Track canonical SquawkNews coverage tagged to DFTX, Definium Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 34 indexed stories across 18 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
As Trump backs psychedelics research, FDA weighs safety and access standards
By Nancy LapidThe U.S. FDA heard calls for clear safety and access standards for psychedelic therapies at a public meeting, the latest step in the Trump administration's push to speed development of treatments such as ib
REGULATION | Sep 15, 2026, 03:16 PM UTC
L
Definium Therapeutics Is Maintained at Buy by Canaccord Genuity
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 02:25 PM UTC
L
Definium Therapeutics Is Maintained at Outperform by Baird
Ratings actions from Benzinga: GMT) Definium Therapeutics Price Target Raised to $79.00/Share From $75.00 by BairdRatings actions from Benzinga
NEWS | Sep 15, 2026, 01:00 PM UTC
L
FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace
By Puyaan Singh and Kamal ChoudhuryThe U.S. FDA is holding a public hearing on Monday to gather feedback on the potential therapeutic use of psychedelic drugs, the latest step in a months-long push by President Donald Tr
REGULATION | Sep 14, 2026, 07:30 PM UTC
H
Definium says LSD-based DT120 eases generalized anxiety in late-stage trial
Definium Therapeutics said its LSD-based DT120 reduced symptoms of generalized anxiety disorder in a second successful late-stage study.
EARNINGS | Sep 14, 2026, 11:55 AM UTC
L
DFTX Stock Jumps Overnight As Investors Brace For Phase 3 Results From LSD-Based Anxiety Drug
Shares of Definium Therapeutics (DFTX) jumped 2% overnight late Sunday as investors awaited topline results from Panorama, the company’s second Phase 3 study of its LSD-based DT120 tablet in adults with generalized anxie
EQUITY | Sep 14, 2026, 01:23 AM UTC
L
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological
NEWS | Sep 13, 2026, 09:00 PM UTC
H
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety
Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological
GEOPOLITICS | Sep 10, 2026, 11:00 AM UTC
M
Definium Therapeutics gets FDA Breakthrough Therapy designation for DT120 ODT
Definium Therapeutics said the FDA granted Breakthrough Therapy designation for DT120 ODT in major depressive disorder after positive Phase 3 results.
REGULATION | Sep 08, 2026, 12:03 PM UTC
L
Definium Therapeutics announces new employee inducement grants
Definium Therapeutics announced new employee inducement grants.
EQUITY | Aug 31, 2026, 08:01 PM UTC
H
Definium Therapeutics Reports Positive Phase 3 Results
Definium Therapeutics announces positive topline results from Phase 3 Voyage Study of DT120 ODT
EQUITY | Aug 12, 2026, 11:01 AM UTC
H
Definium Therapeutics Reports Positive Phase 3 Results
Definium Therapeutics announces positive topline results from Phase 3 Voyage Study of DT120 ODT
EQUITY | Aug 12, 2026, 11:00 AM UTC
L
DFTX - Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
DFTX - Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
EARNINGS | Jul 30, 2026, 08:05 PM UTC
L
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: O
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: OVERWEIGHT @ JPM CLH ITG: BUY @ BAC ARLO WSM: OVERWEIGHT @ Piper ADUR: BUY @ ROTH
EQUITY | Jul 27, 2026, 11:09 AM UTC
H
FDA announces availability of final guidance for psychedelic drug research
The agency said,...
EARNINGS | Jul 15, 2026, 03:12 PM UTC
H
Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors
Jefferies notes that on...
EQUITY | Jul 13, 2026, 05:12 PM UTC
L
Psychedelic: Compass Pathways reports six-month data for psilocybin drug
In this week's "Psychedelic," recurring series focused on psychedelic stock news, looks back on study results, drug delivery evaluation and last patient dosing. COMPASS PATHWAYS REPORTS SIX-MONTH DATA FROM COMP006 TRIAL:
EQUITY | Jul 09, 2026, 01:49 PM UTC
L
Canaccord Genuity Maintains Buy on Definium Therapeutics, Lowers Price Target to $58
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ: DFTX ) with a Buy and lowers the price target from $60 to $58.
EQUITY | Jun 30, 2026, 03:24 PM UTC
L
Top 3 Health Care Stocks That May Keep You Up At Night In June
As of June 30, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a
REGULATION | Jun 30, 2026, 12:55 PM UTC
H
CMPS: Depression Drug 86% Through Phase 3
CMPS' breakthrough-designated depression drug is 86% through its Phase 3 with topline data due this year
EQUITY | Jun 26, 2026, 01:31 PM UTC
H
DFTX Raises $805M
Definium Therapeutics, Inc. closes $805 million upsized public offering, including full exercise of underwriters' option to purchase additional shares
EQUITY | Jun 25, 2026, 08:15 PM UTC
M
DFTX: Jones Trading Raises PT
Jones Trading analyst Justin Walsh maintains Definium Therapeutics with a Buy and raises the price target from $61 to $74
EQUITY | Jun 24, 2026, 06:19 PM UTC
M
DFTX Prices $700M Offering
Definium Therapeutics prices upsized $700M public offering of 20,588,236 common shares at $34.00 per share
EQUITY | Jun 24, 2026, 05:51 AM UTC
M
DFTX: Needham Raises PT
Needham maintains buy rating on Definium Therapeutics and raises price target to $50
EQUITY | Jun 23, 2026, 10:46 AM UTC
M
DFTX Plans $500M Stock Offering
Definium Therapeutics plans to commence a $500M common stock offering
EQUITY | Jun 22, 2026, 08:06 PM UTC
M
DFTX: Oppenheimer Raises Target
Oppenheimer maintains Outperform rating on Definium Therapeutics and raises price target to $60
EQUITY | Jun 22, 2026, 06:00 PM UTC
M
DFTX: Leerink Raises Target
Leerink Partners maintains Outperform on Definium Therapeutics and raises price target to $52
EQUITY | Jun 22, 2026, 06:00 PM UTC
M
Healthcare Stocks Moving
Multiple healthcare stocks are moving in Monday's intraday session, with gainers including Tenon Medical and Aditxt, and losers including Aethlon Medical and Atlantic International
EQUITY | Jun 22, 2026, 05:23 PM UTC
H
DFTX +65% on Phase 3 Results
DFTX shares rise 65% on positive topline results from Phase 3 Emerge Study of DT120
EQUITY | Jun 22, 2026, 01:17 PM UTC
H
APGE +45% on Acquisition
AbbVie to acquire Apogee Therapeutics, sending APGE stock up 45% premarket
EQUITY | Jun 22, 2026, 12:21 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Monday's pre-market session, with gains and losses across the sector
EQUITY | Jun 22, 2026, 12:08 PM UTC
H
DFTX: Meets Efficacy Endpoints
Definium Therapeutics announces topline results from its Phase 3 Emerge study, meeting primary and key secondary efficacy endpoints for DT120 in major depressive disorder
EARNINGS | Jun 22, 2026, 11:20 AM UTC
H
DFTX Reports Positive Phase 3 Results
Definium Therapeutics announces positive topline results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet in Major Depressive Disorder
EQUITY | Jun 22, 2026, 11:00 AM UTC